MA39170B1 - Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer - Google Patents
Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancerInfo
- Publication number
- MA39170B1 MA39170B1 MA39170A MA39170A MA39170B1 MA 39170 B1 MA39170 B1 MA 39170B1 MA 39170 A MA39170 A MA 39170A MA 39170 A MA39170 A MA 39170A MA 39170 B1 MA39170 B1 MA 39170B1
- Authority
- MA
- Morocco
- Prior art keywords
- serine
- cancer
- treatment
- threonine kinase
- inhibitory compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361912905P | 2013-12-06 | 2013-12-06 | |
| PCT/US2014/068452 WO2015085007A1 (en) | 2013-12-06 | 2014-12-03 | Serine/threonine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39170A1 MA39170A1 (fr) | 2018-04-30 |
| MA39170B1 true MA39170B1 (fr) | 2019-05-31 |
Family
ID=52350292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39170A MA39170B1 (fr) | 2013-12-06 | 2014-12-03 | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US9867833B2 (https=) |
| EP (1) | EP3077401B1 (https=) |
| JP (2) | JP6449293B2 (https=) |
| KR (1) | KR102359759B1 (https=) |
| CN (1) | CN106029672B (https=) |
| AR (1) | AR098647A1 (https=) |
| AU (1) | AU2014360455B2 (https=) |
| BR (1) | BR112016012844B1 (https=) |
| CA (1) | CA2932729C (https=) |
| CL (1) | CL2016001368A1 (https=) |
| CR (1) | CR20160309A (https=) |
| EA (1) | EA031243B1 (https=) |
| IL (1) | IL246017B (https=) |
| MA (1) | MA39170B1 (https=) |
| MX (1) | MX368443B (https=) |
| MY (1) | MY176049A (https=) |
| PE (1) | PE20160886A1 (https=) |
| PH (1) | PH12016501071B1 (https=) |
| SG (1) | SG11201604573WA (https=) |
| TW (1) | TWI557126B (https=) |
| UA (1) | UA120506C2 (https=) |
| WO (1) | WO2015085007A1 (https=) |
| ZA (1) | ZA201604461B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015533151A (ja) | 2012-10-16 | 2015-11-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | セリン／スレオニンキナーゼ阻害剤 |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| EP3077401B1 (en) | 2013-12-06 | 2018-04-18 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| KR102379517B1 (ko) | 2013-12-30 | 2022-03-25 | 제넨테크, 인크. | 세린/트레오닌 키나아제 억제제 |
| JP6642942B2 (ja) * | 2013-12-30 | 2020-02-12 | アレイ バイオファーマ、インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| RS60155B1 (sr) * | 2015-11-09 | 2020-05-29 | Astrazeneca Ab | Derivati dihidroimidazopirazinona korisni za upotrebu u tretmanu raka |
| WO2017180581A1 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| AU2018329925B2 (en) | 2017-09-08 | 2025-05-29 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| CN119350306A (zh) * | 2018-12-13 | 2025-01-24 | 英特维特国际股份有限公司 | 1-[(3r,4s)-4-氰基四氢吡喃-3-基]-3-[(2-氟-6-甲氧基-4-吡啶基)氨基]吡唑-4-甲酰胺制备方法 |
| MX2021014961A (es) * | 2019-06-06 | 2022-01-24 | Hutchison Medipharma Ltd | Compuestos triciclicos y su uso. |
| TW202231282A (zh) * | 2021-02-03 | 2022-08-16 | 大陸商上海拓界生物醫藥科技有限公司 | 稠三環類細胞週期蛋白－依賴性激酶抑制劑及其製備方法和醫藥用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005508358A (ja) * | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| BRPI0615930A2 (pt) * | 2005-09-15 | 2016-08-23 | Painceptor Pharma Corp | métodos de modular a interação de uma neurotrofina e um receptor de neurotrofina, de tratar dor em um indivíduo, de tratar distúrbio inflamatório em um indivíduo, de tratar um distúrbio neurológico em um indivíduo, e de tratar uma doença ou distúrbio associado aos sistemas geniturinário e/ou gastrointestinal de um indivíduo, e, composto |
| CN101679409B (zh) * | 2006-12-22 | 2014-11-26 | Astex治疗学有限公司 | 双环杂环衍生化合物、其医药组合物和其用途 |
| EP2002836B1 (en) * | 2007-05-31 | 2010-10-20 | Nerviano Medical Sciences S.r.l. | Cyclocondensed azaindoles active as kinase inhibitors |
| PT2643322T (pt) | 2010-11-23 | 2017-11-13 | Abbvie Inc | Sais e formas cristalinas de um agente indutor de apoptose |
| CN103635472B (zh) | 2011-02-28 | 2018-01-12 | 阵列生物制药公司 | 丝氨酸/苏氨酸激酶抑制剂 |
| JP6097289B2 (ja) | 2011-08-04 | 2017-03-15 | アレイ バイオファーマ、インコーポレイテッド | セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物 |
| HUE053994T2 (hu) | 2012-03-01 | 2021-08-30 | Array Biopharma Inc | Szerin/treonin kináz inhibitorok |
| AR092253A1 (es) | 2012-08-27 | 2015-04-08 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
| JP2015533151A (ja) | 2012-10-16 | 2015-11-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | セリン／スレオニンキナーゼ阻害剤 |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| EP3077401B1 (en) | 2013-12-06 | 2018-04-18 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| KR102379517B1 (ko) | 2013-12-30 | 2022-03-25 | 제넨테크, 인크. | 세린/트레오닌 키나아제 억제제 |
| JP6642942B2 (ja) | 2013-12-30 | 2020-02-12 | アレイ バイオファーマ、インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| MY188526A (en) | 2014-04-09 | 2021-12-18 | Genentech Inc | Process for the manufacturing of medicaments |
-
2014
- 2014-12-03 EP EP14827591.0A patent/EP3077401B1/en active Active
- 2014-12-03 SG SG11201604573WA patent/SG11201604573WA/en unknown
- 2014-12-03 AU AU2014360455A patent/AU2014360455B2/en not_active Ceased
- 2014-12-03 KR KR1020167017847A patent/KR102359759B1/ko not_active Expired - Fee Related
- 2014-12-03 MY MYPI2016001051A patent/MY176049A/en unknown
- 2014-12-03 JP JP2016536560A patent/JP6449293B2/ja active Active
- 2014-12-03 CN CN201480074890.9A patent/CN106029672B/zh active Active
- 2014-12-03 PE PE2016000741A patent/PE20160886A1/es unknown
- 2014-12-03 WO PCT/US2014/068452 patent/WO2015085007A1/en not_active Ceased
- 2014-12-03 MX MX2016007352A patent/MX368443B/es active IP Right Grant
- 2014-12-03 US US14/559,786 patent/US9867833B2/en active Active
- 2014-12-03 CR CR20160309A patent/CR20160309A/es unknown
- 2014-12-03 EA EA201691177A patent/EA031243B1/ru not_active IP Right Cessation
- 2014-12-03 MA MA39170A patent/MA39170B1/fr unknown
- 2014-12-03 BR BR112016012844-3A patent/BR112016012844B1/pt not_active IP Right Cessation
- 2014-12-03 CA CA2932729A patent/CA2932729C/en active Active
- 2014-12-03 UA UAA201607281A patent/UA120506C2/uk unknown
- 2014-12-05 AR ARP140104549A patent/AR098647A1/es unknown
- 2014-12-05 TW TW103142501A patent/TWI557126B/zh not_active IP Right Cessation
-
2016
- 2016-06-03 CL CL2016001368A patent/CL2016001368A1/es unknown
- 2016-06-05 IL IL24601716A patent/IL246017B/en active IP Right Grant
- 2016-06-06 PH PH12016501071A patent/PH12016501071B1/en unknown
- 2016-06-30 ZA ZA2016/04461A patent/ZA201604461B/en unknown
-
2017
- 2017-09-14 US US15/705,104 patent/US10278975B2/en active Active
-
2018
- 2018-11-09 JP JP2018211421A patent/JP2019034970A/ja active Pending
-
2019
- 2019-02-27 US US16/286,955 patent/US10517878B2/en active Active
- 2019-11-11 US US16/680,221 patent/US10842799B2/en active Active
-
2020
- 2020-10-20 US US17/075,380 patent/US11376260B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39170A1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
| ZA202003176B (en) | Compounds useful as kinase inhibitors | |
| MA42109A (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| MA41251B1 (fr) | Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk | |
| CA2871471C (en) | Dna-pk inhibitors | |
| MX383213B (es) | Inhibidores de tirosina-cinasas | |
| MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
| EA201692166A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
| EA201490493A1 (ru) | Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы | |
| MX344335B (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| MA34797B1 (fr) | Hétéroaryles et leurs utilisations | |
| EA201790818A1 (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 | |
| MA37439A1 (fr) | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). | |
| MA35895B1 (fr) | Inhibiteurs d'iap | |
| EA201590268A1 (ru) | Ариллактамные ингибиторы киназы | |
| EA201790206A1 (ru) | Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4 | |
| EA201591180A1 (ru) | Составы ингибитора lfa-1 | |
| EA201590787A1 (ru) | Замещенные пиридопиразины в качестве ингибиторов syk | |
| EA201501187A1 (ru) | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний | |
| MA38009B1 (fr) | Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer | |
| EA201500736A1 (ru) | Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов | |
| EA201500737A1 (ru) | Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов | |
| MX2015009678A (es) | Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4). | |
| MA38591A1 (fr) | Héteroaryldihydropyrimidines pontées en position 6 pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b | |
| UA110724C2 (uk) | Гідроксиметиларилзаміщені піролотриазини як інгібітори alk1 |